Taken together, the approval and clinical application of some kinase inhibitors, including the JAK1/2 inhibitor Ruxolitinib and the ROCK2 inhibitor belumosudil, is promising to better control acute and chronic GvHD after allo-HCT, thereby making allo-HCT available for more patients with severe hematological malignancies. The gene discussed is ROCK2; the disease is graft versus host disease.